Arcutis Biotherapeutics: Cortisone-Free Ointment ZORYVE as a new Alternative for Eczema
Reading Time: 3 minutes
Rapid Revenue Increase: ZORYVE is growing with +471% revenue in 2024 and establishing itself as an alternative to steroids. Profitability in Sight: Analysts forecast break-even by 2026, but unexpectedly strong revenue growth could enable earlier profitability. Arcutis Biotherapeutics (NASDAQ: ARQT) is a California-based biotechnology company specializing in dermatology. The company develops and markets innovative therapies for chronic inflammatory skin diseases. Its main product is ZORYVE, a non-steroidal ointment for the treatment of psoriasis,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
